Eli Lilly (LLY) director Juan Luciano defers compensation into stock units
Rhea-AI Filing Summary
Eli Lilly and Company director Juan R. Luciano reported an acquisition of company common stock through the deferral of board compensation. On January 20, 2026, he acquired 15.286 shares of Eli Lilly common stock at a price of $1,041.29 per share, recorded as an "A" transaction. After this transaction, he beneficially owned 16,756.656 shares of Eli Lilly common stock in direct ownership.
According to the disclosure, Mr. Luciano elected to defer his cash compensation into stock units under the Lilly Directors' Deferral Plan. These deferred stock units will be settled in shares of common stock after he separates from service as a director, meaning the award is part of his director compensation structure rather than an open-market purchase.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 15.286 | $1,041.29 | $16K |
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Eli Lilly (LLY) director Juan R. Luciano report?
Juan R. Luciano reported an acquisition of 15.286 shares of Eli Lilly common stock on January 20, 2026, designated as transaction code "A".
Was the Eli Lilly (LLY) director transaction an open-market purchase?
No. The filing states that the shares were acquired through the Lilly Directors' Deferral Plan, where cash compensation was deferred into stock units rather than an open-market purchase.
How and when will the deferred Eli Lilly (LLY) stock units for Juan R. Luciano be settled?
The footnote explains that the stock units will be settled in shares of common stock following Juan R. Luciano's separation from service as a director.
What is Juan R. Luciano’s relationship to Eli Lilly (LLY)?
The Form 4 identifies Juan R. Luciano as a director of Eli Lilly and Company and not a 10% owner or officer.